Evidence map›Paper›PMID 18799288›Full record

Trial reportSchizophrenia research2008

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.

Donald C Goff, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green

2 registry-linked trialsOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Schizophrenia research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 7 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00455702 phase4completednot on this map

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals

TypeinterventionalSponsorMassachusetts General HospitalRan2004 to 2007Enrolled38ConditionsSchizophreniaArmsd-cycloserine
NCT02304432 early_phase1completednot on this mapstarted 2015, after this paper: background citation

Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine

TypeinterventionalSponsorMclean HospitalRan2015 to 2017Enrolled2ConditionsSchizophrenia, Bipolar DisorderArmsD-cycloserine, DCS or placebo
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 7 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Natural Medicines for Psychotic Disorders: A Systematic Review.The Journal of nervous and mental disease · 2018
    Pooled it
  5. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.The international journal of neuropsychopharmacology · 2016
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Donald C GoffMassachusetts General Hospital, Psychiatry Department, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, USA. goff@psych.mgh.harvard.edu
Corinne Cather
Jennifer D Gottlieb
A Eden Evins
Jared Walsh
Lisa Raeke
Michael W Otto
David Schoenfeld
Michael F Green
Massachusetts General Hospital · USLemuel Shattuck Hospital · USBoston University · USVA Greater Los Angeles Healthcare System · US

Funding

NMDA RECEPTOR FUNCTION IN SCHIZOPHRENIAP50MH060450 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI COYLE, JOSEPH T. · 2000 to 2010
$15.4M
New Treatment and Mechanisms in SchizophreniaK24MH002025 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI GOFF, DONALD C. · 2001 to 2011
$1.6M
NIMH NIH HHS 2 K24 MH002025-06NIMH NIH HHS 2 P50 MH0060450-08A1NIMH NIH HHS K24 MH002025NIMH NIH HHS P50 MH060450
6 · The paper itself

Abstract

backgroundDaily dosing with d-cycloserine has inconsistently improved negative symptoms in schizophrenia patients, whereas intermittent dosing significantly facilitated exposure-based therapy in two studies of patients with phobic anxiety. In animal models, single-dose administration enhances memory consolidation, but tachyphylaxis develops with repeated dosing. The objective of this exploratory study was to assess whether once-weekly dosing with d-cycloserine will produce persistent improvements in negative symptoms and cognition.

methodsFifty stable adult schizophrenia outpatients treated with any antipsychotic except clozapine were enrolled and 38 were randomized, double-blind, in a parallel-group, eight-week add-on trial of d-cycloserine 50 mg or placebo administered once-weekly. Symptom rating scales and a cognitive battery were administered at baseline and week 8 before the dose of study drug. As an exploratory analysis of memory consolidation, the Logical Memory Test, modified to measure recall after 7 days, was administered at baseline and after the first weekly dose of d-cycloserine. The primary outcome measures were change from baseline to week 8 on the SANS total score and on a composite cognitive score.

resultsThirty-three subjects (87%) completed the trial. d-cycloserine significantly improved SANS total scores compared to placebo at week 8. Cognitive performance did not improve with d-cycloserine at 8 weeks. Delayed thematic recall on the Logical Memory Test was significantly improved with the first dose of d-cycloserine compared to placebo. Performance on immediate thematic recall and item recall on the Logical Memory Test did not differ between treatments.

conclusionsOnce-weekly dosing with d-cycloserine for 8 weeks produced persistent improvement of negative symptoms compared to placebo, although statistical significance was, in part, the result of worsening of negative symptoms with placebo. Consistent with animal models, a single dose of d-cycloserine facilitated memory consolidation tested after 7 days on a test of thematic recall. These results must be considered preliminary since a number of outcomes were examined without correction for multiple tests. These findings suggest that once-weekly dosing with d-cycloserine for the treatment of negative symptoms merits further study, as do d-cycloserine effects on memory consolidation.

Indexed as

Schizophrenic PsychologyAdolescentAdultAgedAntipsychotic AgentsCognition DisordersCycloserineDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansMaleMiddle AgedNeuropsychological TestsPlacebosPsychiatric Status Rating ScalesAntipsychotic AgentsCycloserinePlacebos

Identifiers

PMID18799288
PMCPMC2628436
OpenAlexW2123774291

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.